Index

1-α, 25-dihydroxy vitamin D3 547
5-α-reductase inhibitors 15
AA, *see* arachidonic acid
Aβ aggregation inhibitors 487
Aβ plaque toxicity 481
ABC transporters 624, 632
absorption, distribution, metabolism and excretion/ toxicity (ADME/Tox) 16–17, 33, 387–388, 453
abxicimab 106
ACE, *see* angiotensin-converting enzyme
ACE-inhibitors 231
acetazolamide 76–79, 86–87, 90
acetylcholine 15, 420, 429–430, 432–433, 438, 475–478, 568, 581
acetylcholine esterase inhibitors 15
acetylcholinesterase (AchE) 32, 360, 388, 420, 428, 439, 476, 487
  inhibitors 360, 428, 440, 488
2-acetylphenothiazine (ML171) 267–268
AchE, *see* acetylcholinesterase
AChE, *see* acetylcholinesterase
acid α-glucosidase 640, 642
acquired immunodeficiency syndrome 2
actinic keratosis 539
Activase® 107, 111
activated protein C (APC) 185
activity, 7-ethoxycoumarin hydroxylase 551
acute lymphoblastic leukemia 172, 178, 642
acute lymphoblastic leukemia (ALL) 172, 178, 642
acute myeloid leukemia 7, 9, 24, 643
acute myocardial infarction (AMI) 99, 101–102, 111, 113, 577
acute promyelocytic leukemia (APML) 9, 622
acyl-coenzyme A (CoA) 354, 388
AD, *see* Alzheimer's disease
ADA-SCID 11
ADCs, *see* antibody–drug conjugates
adeno-associated virus 52
adenosine 11, 105, 568, 581, 638
adenosine deaminase (ADA) deficiency 638
adenosine deaminase deficiency 11
ADI, *see* L-arginine deiminase
ADI-PEG20 319
ADME/Tox, *see* absorption, distribution, metabolism and excretion/ toxicity
Adnectins 185
Ado-trastuzumab emtansine 176
ADP-ribosyltransferase 34
advanced glycation end products 254
advanced glycosylation end product-specific receptor (AGER/RAGE) 254
AEDs, *see* antiepileptic drugs
AEI, *see* allelic expression imbalance
Affibodies 185, 189–190

affinity chromatography 55–56, 61, 221, 602
Aflatoxin B1 552
agalsidase α 639
agalsidase β 9, 171, 178, 639
AGER/RAGE, *see* advanced glycosylation end product-specific receptor
albinterferon α-2b 172, 180
Alcalase 231–232
Alcanivorax borkumensis 548
alcoholism 402
aldehyde oxidase 34, 270, 506
aldehyde oxidase (AOX) 34, 270, 506
  inhibitor binding 517
  nitro-reduction 525
  substrate binding 516–517
alfimeprase 123
alirocumab 20
alkaline phosphatase (ALP) 640
ALL, *see* acute lymphoblastic leukemia
all-trans retinoic acid (ATRA) 599, 623
allelic expression imbalance (AEI) 403
alopecia 2
ALP, *see* alkaline phosphatase
alteplase 107, 111–112, 114–116
altered biosynthesis 727
altered glycan theory 688
altitude sickness 75
Alzheimer's amyloid β-protein precursor inhibitor (APPI) 192
Alzheimer's disease 19, 31, 397, 408, 427, 473–474, 476, 478, 480, 482, 484, 486, 488, 490, 492, 494–496, 498, 679
Alzheimer's disease (AD) 19, 31, 397, 408, 427, 473–474, 476, 478, 480, 482, 484, 486, 488, 490, 492, 494–496, 498, 679
Alzheimer's disease, treatment 427, 479, 486, 496
amediplase 116
AMI, *see* acute myocardial infarction
amino acid depletion therapies 313–314
amino acid deprivation 312–338, 340–341
amitriptyline 541, 544, 553
amoxicillin 727
AmpliChip cytochrome P450 genotyping test 33
AMPs, *see* antimicrobial peptides
α-amylase 655
amyloid β (Aβ) peptides 420, 480
amyloid β precursor protein (APP) 480
amyloidogenic cascade 489
anakinra 292
analgesics 33, 85, 237, 240
anaplastic lymphoma kinase 24
anastrazole 539, 541
androgen receptor (AR) 599
androgens 539, 541
angina 2, 28, 261
angiogenesis 13, 229, 234–235, 237, 251, 550, 579, 586–587, 620, 693, 707
angiotensin-converting enzyme (ACE) 358
angiotensin II 258, 568, 579–582, 585
anistreplase 107, 113
anthracyclines 624
anti-apoptotic proteins 600
anti-GPCR antibodies 183–184
anti-hypertensive drugs 230
anti-malarial drugs 521
anti-tuberculosis drugs 538, 557
anti-tumor drugs 521, 523, 597, 600

anti-tumor therapies 701
anti-viral drugs 521
antibodies 15, 31, 46, 55, 57, 59, 87–88, 103–104, 171, 173, 175–177, 183–185, 187–188, 292, 597, 607, 631, 642, 658, 661, 696
  bispecific 88, 177
antibody-dependent cellular cytotoxicity 177
antibody-dependent cellular phagocytosis 177
antibody fragments 46, 56–57
antibody–drug conjugates (ADCs) 176
anticalin 185, 187–188
Anticalins 185, 187
antiepileptic drugs (AEDs) 78, 81, 83
antifungal agents 538
antifungals 85
antigen presentation 688, 702
antimetabolites 624
antimicrobial peptides (AMPs) 206, 213, 226, 232–233, 235, 237, 691–692, 696
antioxidant response elements (ARE) 292
antioxidants 249, 274–276, 278–279, 281, 289–290, 294, 489, 491–492
  endogenous 249, 274–276, 290
  enzymatic 249, 274–276, 294
  exogenous 274, 289
  non-enzymatic 274–276
  polyphenolic compounds 274, 491
  vitamins 274, 289–290
antioxidin-RL peptide 289
antiparasitic therapy 701
α2-antiplasmin 100
antiplatelet drugs 105–106, 585
antipsychotic agents 507
antisense oligonucleotides 605
antithrombin III (AT) 105
AOX, *see* aldehyde oxidase
AOX genes 508, 510–511, 524
AOX isoenzymes 506–509
  gene organization 509, 511
  phylogenetic tree 509
  phylogeny 509
AP2238 445–446
APC, *see* activated protein C
APML, *see* acute promyelocytic leukemia
apocynin 268
apoptosis 12–13, 47, 85, 229–230, 238, 250–251, 266, 274, 279–280, 330, 575, 598–599, 603, 620, 626, 648, 650, 688
apoptosis induction 229
APP, *see* amyloid β precursor protein
APPI, *see* Alzheimer's amyloid β-protein precursor inhibitor
AR, *see* androgen receptor
arachidonic acid (AA) 249, 270, 273, 568–569
ARE, *see* antioxidant response elements
argatroban 104
ArgI, *see* Arginase I
arginase (rhARGI) 313–314, 316, 323–324, 339–340
  Co-rhArgI–PEG 326
  rhArgI-PEG 340
Arginase I (ArgI) 323–324
  catalytic mechanism 322
  structure 326–327
  therapeutic use 325
arginine 42, 44, 172, 178, 182, 185, 267, 312–319, 323, 339–340, 643
arginine deprivation 340, 643

argininosuccinate lyase (ASL) 316
argininosuccinate synthase (ASS) 316
aromatase 539
arsenic trioxide 606, 623
Artemisia annua 724, 728
artemisinin 559, 724, 727–730, 738
arterial hemodynamics 248
arterial inflammation 272
arthritis 2, 8, 12, 15, 85–86, 173–174, 187–188, 289, 537, 703
ascorbic acid 276, 279, 290
Asfotase alfa 640
ASL, *see* argininosuccinate lyase
ASNase-I 330
ASNase-II 330–332
asparaginase 178, 313–314, 329, 642–643, 647, 654–655
asparaginase (ASNase) 313–314, 329
asparaginyl endopeptidase 701
aspartic proteases 211–212
Aspergillus niger 399
aspirin 77, 80, 86, 100, 102, 105–106, 116, 583–585
ASS, *see* argininosuccinate synthase
ASS234 443
astemizole 543
AT, *see* antithrombin III
atezolizumab 4
atherogenesis 271, 568, 571–572, 581, 587
atherosclerosis 140, 248–249, 258, 263, 267, 270–271, 283, 289, 570, 573, 583–584
atherothrombosis 140, 253–254, 570, 572, 583
ATM-CHK2 signaling pathways 625
atorvastatin 716–717
ATR-CHK1 signaling pathways 625
ATRA, *see* all-trans retinoic acid
autoimmune diseases 78, 179, 193
avanafil 293
avermectins 731
Avimers 185, 190
7-azaindole structure molecule, *see* GSK2795039
AZT 280

B-cell activation 704
B-cell receptor 702–703
BACE-1 inhibitors 482, 484, 494
  LY 2811376 484
  LY 2886721 484
Bacillus amyloliquefaciens 53, 132
Bacillus brevis 58
Bacillus megaterium 536, 651
bacterial cell wall 48
bacterial CYP enzymes 536, 538, 543, 550
bacteriocins 227, 691
bacteriophage P22 651
bafibrinase 132
barbiturates 78, 80
BBB, *see* blood–brain barrier
BchE, *see* butyrylcholinesterase
BCR-ABL protein 608
benazepril 230
benign prostatic hyperplasia 2, 15
Benzonase 51–52, 54
2-(2-hydroxy-3-methoxyphenyl) benzothiazole (BMBT) 388
4-benzoyl-N-butyl-1,8-naphthalimide (MPN) 389
betaine-homocysteine methyltransferase (BHMT) 334
bevacizumab 171
BHMT, *see* betaine-homocysteine methyltransferase

bioactive peptides 206–218, 220, 222, 224, 226–240, 289
characterization methods 221
cytomodulatory agents 237
enzymatic synthesis 217
mechanism 211
food-based 289
immunomodulatory agents 235
ligation strategies 216
nanoformulations 225, 239
pharmaceutical application 227, 229, 231, 233, 235, 237, 239
purification 214, 217–218, 240
solid-phase peptide synthesis 209
synthesis 206–218, 220, 222, 224, 226, 228, 230, 232, 234, 236–238, 240
biodegradability 647, 653, 656
biofilm 226, 228, 232
biogenic amines 398, 408–409
biopharmaceutical manufacturing 42, 44, 49, 57, 62
biopharmaceuticals 3, 14, 19, 41–44, 46, 48–54, 56, 58–64
biosimilars 14, 24
biosynthesis 89, 714–715, 720–725, 727–738
bivalirudin 104
BK channels 578
blastomas 618
blood coagulation 100, 104, 570, 587
blood pressure 140, 230–232, 248, 258, 281, 551, 556, 578–579, 581–582
blood–brain barrier (BBB) 32, 419, 449, 625, 692, 705
BMBT, *see* 2-(2-hydroxy-3-methoxyphenyl) benzothiazole
BNPP, *see* bis(4-nitrophenyl)phosphate
bradykinin 192, 568, 573, 581
BRD4, *see* bromodomain-containing protein 4
BRD4-selective degrader 609
breast cancer 24, 171, 173, 176, 230, 320, 548, 625, 628, 658
breast cancer stem cells 628
breast tumors 600
brentuximab vedotin 176
bromodomain-containing protein 4 (BRD4) 600
Bruton's tyrosine kinase (BTK) 602
BTK, *see* Bruton's tyrosine kinase
BuChE, *see* butyrylcholinesterase
budesonide 7–8
burosumab 7
buspirone 543
butyrylcholinesterase (BchE) 360, 388, 420, 429, 476
butyrylcholinesterase (BuChE) 360, 388, 420, 429, 476
inhibitors 360

C-reactive protein (CRP) 287, 359, 388
C-type lectin receptors 704
CAD, *see* coronary artery disease
CADD, *see* computer-aided drug discovery
CAIs, *see* carbonic anhydrase inhibitors
camphor 549
camptothecin 389, 624, 660
cancer 2, 4–7, 13, 15, 17, 19, 24–25, 28, 30, 85–88, 171, 176, 228–230, 237–238, 288, 311–314, 316–318, 320, 322–324, 326, 328–332,

334–336, 338–341, 355–356, 419, 520–521, 523, 538, 586–587, 610–611, 618–632, 642–643, 650, 652, 655–656, 658, 660–661, 695, 703, 706–708
immunotherapy 88, 623
cancer stem cells 229, 619, 622–623, 627–630
cancer therapy 28, 87, 229, 312–313, 330, 334, 356, 661
canertinib 606
capillary electrophoresis (CE) 221
capsular polysaccharides 50, 52, 54
CAR, *see* chimeric antigen receptor
CAR-T cells 632
carbamazepine 83–84, 551, 556
carboligase 719
carbonate dehydratases 73
carbonic anhydrase inhibitors (CAIs) 74, 76–78, 80, 82, 84, 86, 88, 90
carbonic anhydrases (CAs)
catalytic mechanism 86
inhibitors
antitumor agents 86
mitochondrial isoforms 75
carboplatin 88, 540–541
carboxylesterases (CES) 349, 351–354, 356, 363, 366–367, 369, 371, 373, 376, 380, 382, 385–386, 388
carboxypeptidase A 46, 55
carboxypeptidase B 46, 55–56, 212
carcinomas 171, 177, 316, 324, 523, 617
cardiovascular disease (CVD) 102–103, 141, 247–248, 250–254, 256, 258, 260, 262, 264, 266, 268–270, 272, 274, 276, 278, 280–282, 284, 286, 288, 290, 292, 294
experimental therapeutics 250, 281
cardiovascular diseases 2, 104, 107–108, 206, 253, 568, 571–573, 575, 577, 579, 581, 583, 585–586
cardiovascular homeostasis 568, 570, 572, 574, 576, 578, 580, 582, 584, 586, 588
cardiovascular therapeutics 173, 184
β-carotene 290, 732
CAs, *see* carbonic anhydrases
CAS, *see* cationic active site
cascades 255, 482–483, 489, 492, 713, 718–719, 738
casein kinase 1α 602
caspase 3 85, 648
caspases 230, 648
catalase 280
catalytic mechanism 74
cathelicidin 232–233
cathepsin B 34
cationic active site (CAS) 430
catumaxomab 171, 177
CD4+T cells 700
CD44 receptor 707
CD47 peptides 661
CE, *see* capillary electrophoresis
celecoxib 84–86, 90
cell apoptosis 13, 230, 238, 250, 279–280
cell cycle 225, 274, 316, 330, 618, 626
cell cycle control factors 626
cell disruption 45, 48
cell lysis 44, 48, 58, 61
cell-penetrating peptides (CPP) 238
CellPrime® rLysozyme 49
cellular IAP1 (cIAP1) 599

cellular retinoic acid binding protein-II 599
cellulase 62
cembranoid β-cembrenediol 545, 554
central nervous system (CNS) 31, 77, 90, 420, 429, 521, 675
cerebral infarction 252, 572
cerebral stroke 268
CES, *see* carboxylesterases
CES1, *see* human carboxylesterase 1
CES2, *see* human carboxylesterase 2
cetuximab 176
Chagas disease 538
checkpoint inhibitors 5, 619, 623, 631–632
checkpoints 88, 630
chemokine receptor (CCRs/CXCR) inhibitors 292
chemotaxis 270, 572
chemotherapy 228, 319–320, 384, 541, 625, 631–632, 643, 653, 660
chimeric antigen receptor (CAR) 5
chimeric fusion genes 620–621
chitinases 45, 48
chitosan 646, 653–654
chlorzoxazone 544, 553
cholinergic neurons 428, 432, 434
cholinergic pathways 428, 433
cholinesterase activity 445, 478, 489
cholinesterase inhibitor 31, 384, 474–477, 479, 482–484, 487, 489, 497
cholinesterases 386, 420, 428–429, 431, 450
  isoforms 428
chromene analogues 487
chromosomal translocation 619–621
chronic obstructive pulmonary disease (COPD) 253
chronic pancreatitis 177, 640
chymosin 62
cIAP1, *see* cellular IAP1
CLEA, *see* cross-linked enzymatic aggregates
clioquinol 495–496
clopidogrel 106, 350, 356, 358, 368–369, 379
clorgyline 414–415, 417
CLUSTAL omega algorithm 509
CNS, *see* central nervous system
CoA, *see* acyl-Coenzyme A
coagulation 100–101, 104, 140, 174–175, 184, 237, 331, 570, 587
coagulation factors 100, 174–175
coevolutionary analysis 168
collagenase 177, 212, 644
combinatorial 34, 170, 189, 676, 678, 683, 713–714, 729, 731–732
combinatorial approach 170
combinatorial biosynthesis 729, 731–732
competitive inhibition 412, 517, 526
complex syntheses 714–738
computational designing 167, 170
  de novo 167
  rational 167–168
  structure-based 169
computational techniques
  inverse docking 681
  molecular docking 681, 683
computer-aided drug discovery (CADD) 675
congenital sucrase-isomaltase deficiency (CSID) 639
conversions, single-step 714–715, 717

COPD, *see* chronic obstructive pulmonary disease
coronary artery disease (CAD) 272, 286–287, 572–573
corticosterone 537, 540
cortisol 548
cortisone 536
coumarin 103, 411, 445–449
coumarin conjugates 447–448
coumarin derivatives 103, 445
coumarin-tacrine hybrid 446
coumarines 491
coumarin–piperazine hybrid 446
COX-2, *see* cycloxigenase-2
COX inhibition 583
COX1, *see* cyclooxygenase 1
CP-31398 626
CPT-11, *see* irinotecan
CRBN-recruiting degraders 608
CRISPR 605, 649
CRISPR-CAS 605
crizotinib 603
CRL1β-TRCP 601
CRL2VHL 601, 610–611
CRL4CRBN 602, 606, 610–611
CRLs, *see* Cullin RING E3 ubiquitin ligases
Crohn's disease 11–12, 174
cross-linked enzymatic aggregates (CLEA) 645
CRP, *see* C-reactive protein
cryptolepine 523
CSID, *see* congenital sucrase-isomaltase deficiency
Cullin RING E3 ubiquitin ligases (CRLs) 600
curcumin 288, 491, 625
curcuminoids 491
Curvularia lunata 558
CVD, *see* cardiovascular disease
cyclooxygenase (COX) pathway 568–569
cyclooxygenase 1 (COX1) 105
cyclooxygenase inhibitors 583
cyclosporine 78, 80, 541
cyclotides 190–191
cycloxigenase-2 (COX-2) 85
CYP, *see* cytochrome P450
CYP enzymes 34, 534–539, 542–543, 549–553, 555, 557–560, 568, 587
  immobilized 558, 560
CYP epoxygenase 568, 574–575, 578
CYP fusion enzyme 550
CYP ω-hydroxylases 569
CYP pathways 568
CYP1A 550, 556
CYP1A1 544, 553
CYP1A2 33, 477, 544, 553
CYP1A9 551
CYP1B1 540, 544, 553
CYP2B 550, 552
CYP2B35 552
CYP2C 550, 556, 570, 573, 575, 577, 587
CYP2C19 33–34, 82, 543, 553
CYP2C8 570, 575, 577, 580
CYP2C9 33, 82, 85–86, 88, 544, 553, 570, 575, 577, 580
CYP2D6 33–34, 85, 544, 553
CYP2E1 537
CYP2J2 570, 574–575, 577–578, 580
CYP3A4 556
CYP3A4/5 541
CYP3A5 33
CYP4A11 551, 579, 582
CYP4F2 579, 582
CYP5A1 569–572, 587
CYP8A1 569–572, 587
CYP19 539, 541
CYP51 538
CYP71D445 539

CYP86 539
CYP101A1 549
CYP102A 537
CYP102A1 536
CYP105 546
CYP105 family 546
CYP105A1 538, 540, 547
CYP105A3 546
CYP106A1 537
CYP106A2 547
CYP153 538, 540
CYP153A 548–549
CYP726A27 539
CYP947 539
CYPBM3 536–537, 540, 543–546, 549, 554
CYPcam 549
cystatin 229, 287
cysteine protease 57, 124–125, 701
cysteine proteases 124, 211–212
cystic fibrosis 7, 29, 51, 172, 177–178, 253, 640, 644
cytochrome b-245 light chain (p22phox, CYBA) 256
cytochrome C 648
cytochrome CYP2C9 88
cytochrome P-450 mono-oxygenases 521
cytochrome P450 (CYP) 33–34, 534, 536, 538, 540, 542, 544, 546, 548, 550, 552, 554, 556, 558, 560, 567, 569, 643, 651
  polymorphisms 33–34
cytochrome P450 (CYP) family 533
cytochrome P450 enzymes 534, 536, 538, 540, 542, 544, 546, 548, 550, 552, 554, 556, 558, 560
  activity 534, 542, 544–545, 550–556, 560
  engineering 534–535, 546–547, 551–553, 555, 560
  limitations 534–535, 557
  substrate diversity 541
cytokines 88, 172, 175, 179–181, 235, 253, 291, 572, 624, 629, 702
  recombinant 179, 181
  therapeutic 88, 172, 179–181
cytomegalovirus (CMV) infection 8
  terminase 8

D-amino acid oxidase (DAAO) 399
D-Amphetamine 414
D-luciferin methyl ester (DME) 356, 372, 389
DAA, *see* D-amino acid oxidase
dabigatran etexilate 104
daltroban 584
DAPase 46, 55
DARPins 185, 188–189
dasatinib 608
data mining 411
DC-SIGN receptor 704
DE, *see* directed evolution
defense regulator peptides (IDRs) 693
dehydroepiandrosterone (DHEA) 538, 540
delta plasmin 121–122
deltamethrin (DMT) 358, 379, 381, 389
dendritic cell 702, 704
2-deoxy-ribose-5-phosphate aldolase (DERA) 716
11-deoxycorticosterone (DOC) 537, 540, 548
deoxycorticosterone acetate (DOCA) 582
11-deoxycortisol 537, 540, 547–548, 555
deprenyl (selegiline) 402–403, 414–417

DERA, *see* 2-deoxy-ribose-5-phosphate aldolase
derivative chromosomes 620
desmoteplase 107, 113, 116–118
DHEA, *see* dehydroepiandrosterone
diabetes mellitus type 2 15, 248, 253, 272
diabetes type 1 89
diabetes type 2 2, 19
diabetic cardiomyopathy 253, 271
diabetic foot ulcers 234
diabetic nephropathy 15
diabetic neuropathy 252
Dicer 626
diclofenac 280, 368–369, 544, 553
diffuse large B-cell lymphoma 5
3,5-dimethyl-8-methoxycarbonyl-BODIPY (DMCB) 389
dipeptidyl-aminopeptidase I 55
dipeptidyl peptidase 4 inhibitors 15
dipeptidyl peptidase-IV 238
directed evolution 30, 161–163, 167, 170, 542, 548, 550, 558, 643
directed evolution (DE) 30, 161–163, 167, 170, 542, 548, 550, 558, 643
Discovery Studio software 680–681
DMCB, *see* 3,5-dimethyl-8-methoxycarbonyl-BODIPY
DME, *see* D-luciferin methyl ester
DMT, *see* deltamethrin
DNA 2, 15, 33, 45, 50–53, 56, 58, 79, 85, 109, 141, 160, 164, 166, 178, 189–190, 230, 240, 250–252, 257, 275, 279, 282, 324, 333–334, 437, 486, 543, 550, 556, 620, 624–626, 644, 646, 648–650, 729, 736
  mitochondrial 279
DNA methylation 333–334
DNA nanostructures 649
DNA origami 649
DNA repair capacity 624
DNA shuffling 166, 543, 550, 556
DNase 45, 51–52, 172, 178, 620, 644
DNase I 51, 172, 178, 620
DNDi, *see* Drugs for Neglected Diseases initiative
DOC, *see* 11-deoxycorticosterone
DOCA, *see* deoxycorticosterone acetate
docetaxel 86, 540–541
docking, molecular 453, 681–682
donepezil 438–444, 447, 453, 455, 457, 463, 474, 476, 489
donepezil derivatives 440
donepezil-lazabemide 442
donepezil-pyridil hybrid 444
dopamine 84, 397, 407–408, 418, 420, 434–435, 437, 475, 485–486
dopamine oxidation 437
dopaminergic cells 409
dopaminergic neurons 408
dorzolamide 76, 79
downstream processing 41–44, 46, 48–54, 56, 58, 60–64, 715, 718
  glycosylation 59–60
  inclusion bodies 42
  microbial cell-based 53
doxorubicin 85, 87, 280, 325, 541, 625
  toxicity 87, 280, 325
driver mutations 619
drug delivery 224, 237, 240, 607, 638, 646
drug design 34, 89, 398–399, 404, 417, 440, 451, 477, 482, 489, 497, 587, 674–676, 678, 680, 682–684

computer-aided 34, 674–676, 678, 680, 682, 684
ligand-based 34, 675, 678, 684
structure-based 34, 404, 675, 680, 684
drug-drug interactions 32, 76, 86
drug metabolites 533–535, 537, 539–540, 552–553, 555, 557–558
drug re-profiling 676
drug-repurposing 676
drug resistance 237, 541, 604, 624
Drugs for Neglected Diseases initiative (DNDi) 29, 34
dual BACE-1 and AChE inhibitors
AP 2243 485
coumestrol 485
dual cholinesterase and MAO Inhibitors 488
Dupuytren's contracture 177
duteplase 115–116
dynamic kinetic resolutions 718

E3-ligase 606, 625
E3-ligase modulators 606
E3 ubiquitin ligases 598, 600, 610–611
ebselen 252
Ecballium elaterium trypsin inhibitor (EETI-II) 191
ECLT, *see* euglobulin clot lysis time
ECM, *see* extracellular matrix
eculizumab 175
edaravone 252
edema 75, 112
cerebral 75, 112
retinal 75
EDHF, *see* endothelial-derived hyperpolarizing factor
EETI-II, *see Ecballium elaterium* trypsin inhibitor
EETs, *see* epoxyeicosatrienoic acids
eGFP, *see* enhanced green fluorescent protein
EGR1 transcription factor 628
eicosanoid synthesis 568
eicosanoids 569, 571, 583, 587
EL35, *see* Polyoxyl 35 castor oil
elastin-like polypeptides (ELP) 55
ELP, *see* elastin-like polypeptides
EMA, *see* European Medicines Agency
embryonic stem cell genes 627
Eminase® 113
endo-β-*N*-acetylglucosaminidases 60
endoglycosidases 60
endopeptidases 48, 53
endoplasmic reticulum (ER) 349, 389, 521, 582, 688
endoproteases 55, 211
endothelial adhesion molecules 258
endothelial-derived hyperpolarizing factor (EDHF) 573
endothelial nitric oxide synthase (eNOS) 273
engineered proteins 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192
enhanced green fluorescent protein (eGFP) 650
enhanced permeation and retention effect (EPR) 656
enkephalin 692, 698
eNOS, *see* endothelial nitric oxide synthase
ensaculin 445–446
enzyme inhibitors 1, 11, 13–15, 31, 34, 41, 73, 99, 159, 205, 247, 311, 349, 358, 397, 427, 473, 505, 533, 567, 597, 603–604, 617, 637, 673, 687, 713

enzyme promiscuity 737
enzyme replacement therapy (ERT) 16, 30–31, 177, 638
eotaxin-3 8
Epicurian coli XL1-red 164
epigenetic regulation 403
epigenomic machinery 32
epilepsy 75, 82, 84, 551
epinephrine 434, 437, 486
epithelial sodium channels 578
epothilone 538
epothilone polyketides 538
epoxyeicosatrienoic acids (EETs) 568–569
  EET analogs 579, 582, 585–587
  EET antagonist 575
  EET-B 582
  EET metabolites 578
  EET modulators 586
EPR, *see* enhanced permeation and retention effect
ER, *see* endoplasmic reticulum
ERα, *see* estrogen receptor α
erectile dysfunction 2, 28
ERRα, *see* estrogen-related receptor α
error prone PCR 164
ERT, *see* enzyme replacement therapy
erythromycin 538, 540, 557
erythromycin A 714
erythromycin D 557
erythropoietin 15, 184, 690
Escherichia coli 45, 53, 56, 58–59, 112, 114, 120–122, 192, 213–214, 227, 330, 336, 517, 519, 536, 538, 550, 556, 643, 696–697, 700, 732–733
Escherichia coli BL21 732
Escherichia coli cells 53
ESCRT-system 630
esomeprazole 543, 553
estrogen receptor α (ERα) 507, 599
estrogen receptor modulators 507
estrogen-related receptor α (ERRα) 601
estrogens 539–541, 557
etanercept 173, 292
eteplirsen 5, 605
ethinylestradiol 83
7-ethyl-10-hydroxy-camptothecin (SN38) 389
etoposide 541
Euclidean distance 676
euglobulin clot lysis time (ECLT) 139
eumiliin 125
Euphorbia lathyris L 539
European Medicines Agency (EMA) 3, 6–7, 48
evasin-3 292
EVB calculations 418
event-driven strategy 603–604
evolocumab 20
exonuclease 45, 53, 164
exoproteases 55, 211
exosomes 624, 628–630, 632
extracellular matrix (ECM) 186, 268, 581, 618, 629

Fabry disease 171, 178, 639
FACS-phenotyping experiments 627
Factor Xa 46, 55, 100, 104–105
Factor Xa inhibitors 104–105
FAD 397–402, 404, 406, 408, 410, 412, 414–416, 418, 420, 434–436, 451, 453, 456, 460, 505–506, 513–517, 519, 526, 545
FAD-containing monoamine oxidases 398–420

FAD-containing oxidases 398–420
FAEEs, *see* fatty acid ethyl esters
familial adenomatous polyposis (FAP) 7
familial hypercholesterolemia 21
FAP, *see* familial adenomatous polyposis
fatty acid ethyl esters (FAEEs) 354, 389
fatty acid ω-hydroxylase 548
FD, *see* fluorescein diacetate
FDA, Food and Drug Administration (USA) 1–8, 16–17, 20, 22–25, 27–29, 31, 33, 50–51, 63, 86, 104–107, 111–112, 121, 124, 171, 177–178, 181, 224, 314, 331, 410, 419, 438, 440, 543, 605, 607, 643, 674, 731
fenamic acid 544, 553
fenbufen 77
Fenton type reactions 486
FFAs, *see* free fatty acids
fibrin 100–102, 107–108, 110–114, 116–121, 123, 129, 134, 139, 644
fibrinogenolysis 118, 123, 125, 128–129, 132–133, 137
fibrinolysis 2, 30, 100–101, 108, 112, 115, 118, 120, 129, 137, 139–140
fibrinolytic enzymes 100, 102, 104, 106–108, 110, 112, 114, 116, 118–120, 122–134, 136–138, 140, 644
fibroblasts, cancer-associated 629
fibrolase 123
FLAG tag 55
flavonoids 252, 274, 277, 375–376, 378, 387
flavourzyme 231–232
fluorescein diacetate (FD) 356, 372, 377, 389
Fondaparinux 105
formaecin 692
fragment-based or de novo design 676, 683
fragment-based or de novo design approaches
  chimera 682
  design tools 683
  fusion 682
  hybrid 683
fragment condensation 207, 215
fragments of antigen binding 175
free fatty acids (FFAs) 253–254
free radical species 250
fulvestrant 606
Fumitremorgin C 625
fungal infections 232
furosemide 78–81, 86
fusion peptides 213
fusion proteins 119, 141, 559
fynomers 186–187

G-CSF, *see* granulocyte colony-stimulating factor
G-protein coupled receptor (GPCR) 183, 238, 571
GA, *see* glycyrrhetinic acid
GAGs, *see* glycosaminoglycans
α-Gal 639
β-Gal, *see* β-galactosidase
galactose-6-sulfate sulfatase 641
β-galactosidase (β-Gal) 648–649
α-galactosidase A 639
galantamine 438, 474, 476
gamma-delta T cell type (CD3+) 701
gamma secretase inhibitors 494
gastrointestinal cancer 320
gastrointestinal diseases 2
Gaucher disease 171, 178, 639–640, 647

GDEPT, *see* gene-directed enzyme prodrug therapy
gefitinib 603
gemcitabine 87, 356, 540–541
gene-directed enzyme prodrug therapy (GDEPT) 644
gene-fusion 543, 550
gene mutations 618, 621
  cancer-specific 618
  mutational landscape 618
Generally Regarded As Safe (GRAS) 49, 731
genetic diseases 688
genetic knockdown technologies 605–606
genistein 550, 555
germ cell tumors 617
GH, *see* growth hormone
Ghosal hemato-diaphyseal syndrome 572
Girentuximab 88
GKT136901 (pyrazolopyridine derivatives) 268
GKT137831 (pyrazolopyridine derivatives) 268
glaucoma 75–77
glioblastoma 87, 318, 325, 334, 523
Glucagon Receptor Element 403
glucanases 45, 48
β-glucocerebrosidase 639
glucose oxidase (GOx) 649, 660
glucose-6-phosphate dehydrogenase 650
α-glucosidase 640, 642
glutamate-cysteine ligase 288
γ-glutamyl transpeptidase 34
glutathione 34, 55, 213, 274–280, 283, 287–288, 333, 486, 650
glutathione peroxidase 275
glutathione S-transferase 55
glutathione transferase 34, 213
glycans 687–690, 693, 696–702, 704–706, 708–709
  high-mannose type 687
glycobiology 689, 692, 705
glycocin-F 690–691, 693
glycocode 688, 708
glycoengineering 690
glycogen branching enzyme 640
glycogen debranching enzyme 640
glycogen phosphorylase 640
glycogen storage disease 178, 640, 642
glycogen synthase 640
glycome 687, 705
GlycoMine 706
glyconanoparticles 691
glycoprotein 59–60, 105–106, 114, 175, 640, 689, 697, 700, 702, 706
glycosaminoglycans (GAGs) 641
glycosidases 48, 688, 705
glycosylation 46, 59–60, 115, 224, 254, 329, 353, 459, 655, 687–693, 695–701, 705–709
  types 689
glycosylation of proteins 691
  C-linked 688–689
  N-linked 688–689
  O-linked 689
  S-linked 688, 690
glycosylation type 688–689
glycosyltransferases 690, 696, 698–699, 705
glycotransferase SunS 690
glycyrrhetinic acid (GA) 370–371, 389
GlyTouCan 698, 706
Gordonia alkanivorans 548
GOx, *see* glucose oxidase
granulocyte colony-stimulating factor (G-CSF) 180–181, 184
granzyme B 648

GRAS, *see* Generally Regarded As Safe
green chemistry 716
growth hormone (GH) 174, 181–183
GSK2190915 (5-LOX activating protein (FLAP) agonist) 271
GSK2795039 (7-azaindole structure molecule) 268

Haemophilus infuenzae 52
hallmarks in cancer 620
hAOX 1 507, 512–520
hAOX1
  oxidation mechanisms 518
  structure 512
Haploinsufficiency 626
harmine 413–414, 460, 462
27-HC, *see* 27-hydroxycholesterol
HCC, *see* hepatocellular carcinoma
HCEC, *see* human epithelial colon cells
HDL-c, *see* high-density lipoprotein cholesterol
HDPs, *see* host defense peptides
heart failure 2, 269, 271–272, 287, 398, 585
heart failure (HF) 2, 269, 271–272, 287, 398, 585
Heberkinasa® 110
hematological tumors 619–621
hemophilia 9, 174, 184–185
hemostasis 100–101
heparin 102–105, 116
heparin-induced thrombocytopenia (HIT) 103
hepatitis C 4–5, 12, 172, 179–180, 237, 291, 630
hepatitis C virus 4–5, 237, 630
hepatocellular carcinoma (HCC) 314, 316, 326, 658
Herpes simplex virus 228, 233
20-HETE, *see* 20-hydroxyeicosatetraenoic acid
HETE, *see* hydroxyeicosatetraenoic acid
HF, *see* heart failure
HIF-1α, *see* hypoxia-inducible factor-α
high-density lipoprotein cholesterol (HDL-c) 254
high-dose hook effect 603
high-performance liquid chromatography (HPLC) 218–220, 700
high-throughput screening (HTS) 160, 162, 268, 389
hirtin 125
hirudin 104, 119
His tag 55
HIT, *see* heparin-induced thrombocytopenia
HLC, *see* human liver cytosol
HLM, *see* human liver microsomes
Hodgkin's lymphoma 10, 171, 316
homoisoflavonoid 457–458
homologous recombination 166–167
horizontal gene transfer 731
horseradish peroxidase 648–649, 651
host defense peptides (HDPs) 693
HPLC, *see* high-performance liquid chromatography
HTS, *see* high-throughput screening
human carboxylesterase 1 (CES1) 350–351, 388
human carboxylesterase 2 (CES2) 350, 388
human epithelial colon cells (HCEC) 229

human genome 597, 626
human liver cytosol (HLC) 389
human liver microsomes (HLM) 355, 389
Humulin 181
Hunter disease 172, 178
Hunter syndrome 641
Huntington's disease 238, 480
Hurler-Scheie syndrome 178
Hurler syndrome 171
hyaluronan 707–708
hybrid proteins 118
27-hydroxycholesterol (27-HC) 379, 389
20-hydroxyeicosatetraenoic acid (20-HETE) 273, 551, 556, 569
hydroxyeicosatetraenoic acid (HETE) 273, 551, 556, 568–569
  20-HETE 569–570, 572, 574, 579–583, 587
  20-HETE inhibitor 583
  HETE deficiency 582
(*R*)-4-hydroxyisophorone 555
17α-hydroxyprogesterone 537
hydroxytamoxifen 600, 653
hypercholesterolemia 21, 248
hyperglycaemia 253, 255, 284, 331, 340
hyperinsulinemia, hypertension 253
hyperpigmentation 232–233
hypertension 9–10, 28, 79, 230, 240, 248–249, 253, 257–259, 262, 265, 268, 282–285, 288, 291, 572, 578–582, 585
hypertensive heart disease 247
hyperuricemia 15, 269, 287
hypophosphatasia 9, 640
hypoxia 86, 258, 268–269, 586, 601
hypoxia-inducible factor 86
hypoxia-inducible factor-α (HIF-1α) 601
hypoxic tumors 75

IAP, *see* inhibitor of apoptosis protein
IAP antagonists 600
ibuprofen, diflunisal 77
ICAM-1, *see* intracellular adhesion molecule
ICU, *see* intensive care unit
Idraparinux 105
IDRs, *see* defense regulator peptides
ifosfamide 541, 544, 553
IgG function 688
IKAROS family transcription factors 602
imatinib 603, 621
imidacloprid 525–526
immune checkpoint inhibitors 5
immune system 175, 179, 272, 624, 631, 660–661, 688–689, 691–692, 700–702, 704, 708
immunity 13, 235, 240, 660, 692
immunoglobulins 175, 661, 699, 703
immunons 704
immunosenescent peptides 701
immunosuppressive drugs 521
in silico approaches 676
in silico studies 675
in silico techniques 675
in vitro recombination 165–166
incremental truncation for the creation of hybrid enzymes (ITCHY) 167
indisulam (E7070) 87–88, 606
Indolicidin 228, 233
indolotacrine analogues 460

inflammatory disorders 537, 708
inflammatory mediators 270
infliximab 292
influenza virus 52
ingenol mebutate 539
inhibitor binding 516
inhibitor of apoptosis protein (IAP) 598
inhibitors, multi-targeted 443
innate immune system and 701
insulin 13, 46, 56–57, 63, 172–173, 181–182, 184, 189, 234, 253–255, 283–284, 288, 574
insulin receptor substrate 1 (IRS1) 253–254
integrase inhibitors 15
intelectins 691
intensive care unit (ICU) 272
intracellular adhesion molecule (ICAM-1) 571
5-iodo-2-deoxyuridine 523
iproniazid 410, 437
iPS cells 628
iPS technology 627
irciniastatin A 717–718
irinotecan (CPT-11) 350, 355–356, 358, 379, 388
IRS1, *see* insulin receptor substrate 1
ischemia 249, 267, 272, 291, 574–577, 583
Isocarboxid 414
isocitrate dehydrogenase 24
isothiocyanates 491
ITCHY, *see* incremental truncation for the creation of hybrid enzymes
ivermectins 731–732

K channels 578
kallikrein 186, 192
Kaplan-Meier curves 622
KEAP, *see* Kelch-like ECH-associated protein 1
KEAP 1-recruiting degrader 610
KEGG, *see* Kyoto Encyclopedia of Genes and Genomes
KEGG Cancer database 695
Kelch-like ECH-associated protein 1 (KEAP) 292
11-keto-β-boswellic acid (KBA) 537
ketoprofen 77
kinase inhibitors 621
knottins 190–191
KRAS 608
kringle domains 111, 120–121, 191–192
Kunitz domain 185, 192
Kyoto Encyclopedia of Genes and Genomes (KEGG) 32, 512

L-amino acid oxidase (LAAO) 399
L-ARG, *see* arginine
L-ARG deprivation 316, 318, 320, 324–325
L-arginine deiminase (ADI) 313–314
  catalytic mechanism 314
  structure 314
  therapeutic use 318
L-asparaginase 647, 654
L-DOPA 402
α-L-iduronidase 641
L-methionine 314, 333–334
LAAO, *see* L-amino acid oxidase
lactic dehydrogenase 650
Lactoferrin 227
ladostigil 420, 450–452, 493
lanoteplase 115

lansoprazole 553
lanthipeptides 693
LDL, *see* low-density lipoprotein
lebetase 123
lectin 688, 691, 700, 704
lectin receptors 688, 704
leishmaniasis 2
lenalidomide 11
lentivirus 52
lepirudin 104
letermovir 7–8
letrozole 539, 541
leukemia disease subtypes 620
leukemias 617, 620–621
leukocyte migration 292, 688
leukocyte rolling 705
leukotriene receptor antagonists (LTRAs) 271
leukotriene receptors 270
levan 654
Levemir 173, 182
lidocaine 544, 553
ligand-based pharmacophore model 678
  available software 679
ligand-based techniques 678
ligand-pharmacophore modelling 273
LIGSITE 676
lipid-linked oligosaccharide (LLO) 698
lipocalins 185, 187
lipogenesis 89
lipoic acid 252, 275, 277, 281, 288
lipopeptides 233
lipopolysaccharide 690, 697
lipopolysaccharides (LPS) 49
lipoprotein lipase 690
liposome 225, 646–648
lipoxins 271
lipoxygenase (LOX) pathway 568–569
lipoxygenases (LOXs) 249, 270
  12/15-LOX 270
  5-LOX 270
(*R*)-lisofylline 556
liver toxicity 415, 525
LLO, *see* lipid-linked oligosaccharide
LMWHs, *see* low-molecular-weight heparins
low-density lipoprotein (LDL) 190, 254, 281
low-molecular-weight heparins (LMWHs) 103
lower urinary tract symptoms 15
5-LOX activating protein (FLAP) agonist, *see* GSK2190915
LOXs, *see* lipoxygenases
LPS, *see* lipopolysaccharides
LTRAs, *see* leukotriene receptor antagonists
lumbrokinase 107, 123–124
lumiflavin 418
lunasin 229
lymphomas 238, 314, 329, 617, 620–621
lysosomal storage diseases 2
lysozyme 45, 48–49, 63, 176, 653

macrophages 235, 237, 253, 255, 262, 264, 288, 355, 571, 629, 639–640, 653, 660, 691, 701
magainin peptide 234
major histocompatibility complex (MHC) 175, 693, 700–704
Malaria 29
malignant pleural mesothelioma 316, 320
maltose binding protein (MBP) 55, 189
mammalian CYP enzymes 536, 542–543, 550–551

mannanases 45, 48
mannose-binding lectin (MBL) 691
mannoside *N*-acetylglucosaminyltransferase 5 703
MAO, *see* monoamine oxidase
MAO A 398–399, 402–404, 406–417
MAO-A-immunoreactive neurons 437
MAO B 397–404, 406–418, 437
MAO-B inhibition 447–448, 454, 457, 486
MAO inhibition 410, 419, 446, 452, 455–456, 459, 486
  antidepressant effect 410
  irreversible 410
  reversible 410
MAO inhibitors (MAOI) 398, 410, 415, 440, 445, 461, 482, 488
MAOI, *see* MAO inhibitors
MAOs, *see* monoamine oxidases
MAP kinase 279
MAPK, *see* mitogen-activated protein kinase
Marinobacter aquaeolei 548–549
Maroteaux-Lamy syndrome 178
matrix metalloproteinases (MMPs) 571
MBL, *see* mannose-binding lectin
MBP, *see* maltose binding protein
MCM, *see* multiple-compound medication
meclofenamic acid 544
mediated drug metabolism 33, 551
medicaid 25
medicare 25–26
mefenamic acid 544
melphalan 87
memantine 438–439, 474, 476, 479–480
memoquin 493
6-mercaptopurine 521
mertansine 176
mesenchymal cells 629
metal chelators 495–496
metalloproteases 123, 128–137, 140, 211–212
METase, *see* methionine-γ-lyase
metastatic melanoma (MM) 179, 181, 316
metastatic pancreatic ductal cancer 87
mETC, *see* mitochondrial electron transport chain
metformin 28
methionine aminopeptidase 2 601
methionine-γ-lyase (METase/MGL) 313–314
  catalytic mechanism 314
  structure 336, 337
  therapeutic use 335
methotrexate 81, 521, 624
methylene blue 413–414
methylthioadenosine phosphorylase (MTAP) 334
MHC, see major histocompatibility complex
MI, *see* myocardial infarction
micelles 646–647
microbial thrombolytic enzymes 119
microplasmin 121
microwave technology 215
midazolam 79, 90, 542
minicircle (MC) DNA vectors 58
minicircle vector purification 46
miniplasmin 120–121
mipomersen 605
mitochondrial complex II 255
mitochondrial electron transport chain (mETC) 249, 254–255, 279

mitochondrial neurogastrointestinal encephalomyopathy 641
mitogen-activated protein kinase (MAPK) 189, 282, 575
MitoQ, *see* mitoquinone
mitoquinone (MitoQ) 290
mitoxanthrones 624
MM, *see* metastatic melanoma
MMPs, *see* matrix metalloproteinases
MMT, *see* multiple-medication therapy
moclobemide 414
mogamulizumab 173, 184
molecular dynamics (MD) simulation study 682
Molecular Operating Environment (MOE) software 703
molybdoflavoenzymes 505
monoamine oxidase (MAO) 15, 31, 84, 397–420, 428, 430, 432, 434–440, 442–463, 482, 485–488, 522
  active site 400–401, 404, 412–414, 416–418, 435–436, 448, 451, 456, 460, 462
  function 433–435, 438, 442, 485
  isoforms 434
  mechanism 84, 399–401, 405, 411, 415–418, 439
  structure 398–399, 401, 404, 411, 416, 418, 434–435, 440, 443, 446, 454, 461, 488
monoamine oxidase inhibitors 15
monoamine oxidases (MAOs) 31, 397–398, 400, 402, 404, 406, 408, 410, 412, 414, 416, 418, 420
  FAD-containing 400
monobodies 186
monoclonal 8, 15, 59, 88, 175–177
monoclonal antibodies 15, 59, 88, 175–176
monocyte differentiation 255
monomethyl auristatin E 176
monteplase 116
morphine 99
Morquio syndrome 641
MPN, *see* 4-benzoyl-N-butyl-1,8-naphthalimide
MPO, *see* myeloperoxidase
MPO inhibitor, *see* PF-1355
MPS, *see* mucopolysaccharidosis
MSA, *see* multiple sequence alignment
MTAP, *see* methylthioadenosine phosphorylase
MTDL, *see* multitarget drug ligand
Mucin-6 protein 699
mucopolysaccharidosis (MPS) 641
multidrug resistance 227, 624
multiple-compound medication (MCM) 674
multiple-medication therapy (MMT) 674
multiple myeloma 10, 355, 602
multiple sclerosis 4, 29, 171, 673
multiple sequence alignment (MSA) 168
multistep conversions 714–715, 718, 738
multitarget directed ligands 674
multitarget-directed ligands 31
multitarget drug design (MTDD) approach 398, 417, 477, 482–483, 489, 497, 673–674, 677, 679–680, 683
multitarget drug designing (MTDD) 674–677, 679–681, 683
multitarget drug ligand (MTDL)
  AD therapy 453
  design 682
  semicarbazone derived 459
  thioxanthone derivatives 460
multitarget drugs 398, 417, 419–420

multitarget ligand design 475, 477, 483, 485, 487, 489, 491, 493, 495
multitarget QSAR Models 679
multitargeted inhibitors 444
multivesicular body (MVB) 630
mutagenesis 118, 164–165, 181, 185–186, 337, 517, 542–544, 546–553, 555–559, 643
  chemical 164, 554–555, 557, 559
  focused 164–165, 181
  random 164–165, 542, 544, 546–547, 550–551, 553, 555, 557–558
mutasynthesis 727, 734, 736–738
mutasynthons 736–738
MVB, *see* multi-vesicular body
Mycoplasma arginini 320
myeloperoxidase (MPO) 272, 287
myocardial infarction (MI) 2, 99–102, 111–114, 184, 273, 573, 577, 580

N-acetylgalactosamine-4-sulfatase 641
N-acetylglucosamine 48, 689, 705
N-acetylglucosaminidase 697
N-acetylmuramic acid 48
N-acetyltransferases 34
NADPH antagonists 259
NADPH oxidases 249, 258
  isoforms (NOX1, NOX2, NOX3, NOX4, NOX5) 258
nano-emulsions 225, 234
nanobioreactors 645–647, 649–655, 657, 659
  tissue targeting 655
    active 657
    efficiency 655
    passive 656
nanobodies 188
nanocages 649–650
nanocarriers (NCs) 237, 638, 646, 656, 691
  multifunctionality 659
  multitargeting 660
nanodisc system 560
nanoencapsulations 225
nanomedicine 637–638
nanoparticles (NPs) 225, 230, 232, 239, 638, 645–646, 650, 653–654, 656
  core–shell 650
  PEGylated 648
  virus-like 651
nanotechnology 159, 230, 240, 637
nanotubes 649
α-naphthoflavone activity 551
naproxen 543–544, 553
nargase 45, 54
native biosynthesis 720, 722–725, 729–730
native chemical ligation (NCL) 216
nattokinase 107, 132, 134, 137, 139–140
NCAMs, *see* neural cell adhesion molecules
NCL, *see* native chemical ligation
NCs, *see* nanocarriers
Neisseria meningitidis 52
neoplastic transformation 629
neural cell adhesion molecules (NCAM) 236
neurodegenerative diseases 2, 31, 240, 252, 397–398, 420, 473, 673
neurotransmitter metabolism 407–408
neutrophil cytosol factor 2 (p67phox, NCF2) 256
neutrophil cytosol factor 4 (p40phox, NCF4) 256

neutrophils 235, 237, 260, 660
new molecular entities (NMEs) 3, 674
NF-kB (NF-kappaB) antagonists 293
NFE2L2, *see* nuclear factor erythroid 2-related factor 2
NGlycPred 707
nicking endonuclease 58
nifedipine 573
nitric oxide 100, 231, 250, 252, 254, 273, 282, 287–288, 413, 581
nitrogen dioxide 252
nivolumab 607
NMDA receptor 438–439, 475, 479–480, 482–483, 497
NMDA receptor antagonist 438–439, 479–480
NMEs, *see* new molecular entities
non-Hodgkin's lymphoma 5, 12, 314, 316, 320
non-homologous recombination 166–167
non-nucleoside reverse transcriptase inhibitors 625
non-ribosomal peptides 729
non-small cell lung cancer (NSCLC) 24, 320, 540
non-steroidal anti-inflammatory drugs/NSAIDs 544
noradrenaline 408
norepinephrine 420, 434–435, 485–486
NPs, *see* nanoparticles
NSCLC, *see* non-small cell lung cancer
nuclear factor erythroid 2-related factor 2 (NFE2L2) 292
nucleoside reverse transcriptase inhibitors 625
nusinersen 5, 605

OA, *see* oleanolic acid
ocriplasmin 121
OGT, *see* oligosaccharyltransferase
Ojima lactone 728
oleanolic acid (OA) 369, 371, 389
oligonucleotide therapeutics 605–606
oligosaccharyltransferase (OGT) 697
omega-3 PUFA family 570
omega-6 PUFA family 570
Oncaspar 178, 331
ONCOFID-P 707
ONCOFID-S 707
oncogenes 50, 618, 620
oncogenic proteins 597–600, 602–603, 605–606, 608, 611
oncogenic signaling pathways 621
OPs, *see* organophosphates
organophosphates (OPs) 386, 389
ornithine transcarbamylase (OTC) 317, 323
orphan drugs 1, 7, 9, 24
OSCARR 165
OSMAC 723–724
osteoporosis 547, 673
osteosarcoma 541
OTC, *see* ornithine transcarbamylase
ototoxic drugs 81
oxidative stress 75, 248–250, 252–254, 256–258, 260, 262, 264, 266, 268, 270–272, 274–276, 278–290, 292, 294, 333, 436–437, 439, 462, 480–481, 486, 490, 492, 496, 582, 660
  drug induced 250, 278–280

experimental therapeutic agents 250, 281–283, 288
Oxypurinol 270

P-selectin 268, 571
P2Y12 receptor inhibitor 106
p22phox, CYBA, *see* cytochrome b-245 light chain
p40phox, NCF4, *see* neutrophil cytosol factor 4
p53 pathway 624
p53 protein 625–626
p53 tetramers 626
p67phox, NCF2, *see* neutrophil cytosol factor 2
P450 family 409
P450 hydroxylases 251, 273
P450 isoflavone synthase 1 550
PACE, *see* phage assisted continuous evolution
paclitaxel 540–541, 724, 727–729, 738
PAI-1, *see* plasminogen activator inhibitor 1
PAIs, *see* plasminogen activator inhibitors
pamiteplase 115
PAMPs, *see* pathogen-associated molecular patterns
pancreatic cancer 320, 643
pancreatic carcinoma 316, 325
pancreatic enzyme replacement therapy 177
pancreatic tumors 640
Pantoea ananatis 732–733
papain 46, 57, 212
paracetamol 253, 278, 280
parental plasmid (PP) 58
pargyline 410, 414–417
Parkinson's disease 2, 15, 84, 238, 291, 398, 402, 409–410, 417, 480, 486
PARP, *see* poly ADP ribose polymerase inhibitors
partial thromboplastin time (PATT) 139
PAS, *see* peripheral anionic site
PASS 676
passenger mutations 619
patent ductus arteriosus (PDA) 7
pathogen-associated molecular patterns (PAMPs) 700
PATT, *see* partial thromboplastin time
PCSK9, *see* proprotein convertase subtilisin kexin 9 inhibitors
PD-1/PD-L1 pathway 607
PDA, *see* patent ductus arteriosus
PDTC, *see* pyrrolidine dithiocarbamate
pectinase 62
pegaptanib 605
pegfilgrastim 172
PEGylated protein 639
PEGylation 178, 180, 188, 652, 661
penicillin G 734
penicillin V 734–735
Penicillium chrysogenum 128, 546, 735
pepsin 46, 57–58, 63, 212, 227, 231
peptide-mimetic 237
peptide-nanoparticle hybrids 230
peptide vaccines 237
peptides 205–216, 218, 220, 222, 224, 226–240, 691–693, 695, 697
  animal derived 206, 231
  food derived 227, 231
  marine-derived 237
  plant derived 206, 231

peptidoglycan 48–49, 54
peptidoglycan *N*-acetylmuramoylhydrolase 48
PERFORM study 584
perillyl alcohol 538, 540
peripheral anionic site 430
peroxisome proliferator-activated receptor gamma (PPARG) 254–255, 268
peroxynitrite 250, 252
personalized medicine 621
pesticides 536, 731
PET, *see* positron emission tomography
Pexiganan 234
Peyronie's disease 644
PF-1355 (MPO inhibitor) 273
PGI2, *see* prostacyclin
PH2, *see* prostaglandin
phage assisted continuous evolution (PACE) 166
phage display 186–187, 189, 192
pharmaceutical discoveries 721
pharmacophore modeling 678–680
  complex-based 680
  structure-based 678, 680
  target (only)-based 680
    available databases 681
pharmacy benefit managers 26
phase I drug metabolism 506, 508, 510, 512, 514, 516, 518, 520, 522, 524, 526
Phenelzine 401–402, 414, 416
phenylalanine hydroxylase 642
Phenylketonuria 642
phosphatidylinositide 3-kinase (PI3K) 254
phosphodiesterase type 4 inhibitors 15
phosphodiesterase type 5 (PDE-5) inhibitors 81
phospholipase A2 (PLA2) 273, 568, 655
phospholipids 251, 273, 568–569
phthalazines 513, 516–518, 524
phyto-peptides 229
  anti-cancer agents 229
PI3K, *see* phosphatidylinositide 3-kinase
PI3K-Akt pathway 253
Pichia pastoris 57, 121, 186, 227, 404, 709
Pictet-Spenglerase 719
pirlindole 414
piscine 551
PKA, *see* protein kinase A
PKC, *see* protein kinase C
PKD, *see* polycystic kidney disease
PLA2, *see* phospholipase A2
plasmid DNA vectors 52
plasmin 100–101, 107–113, 115, 117–122, 128–129, 132, 139–141, 644
plasmin inhibitors 108, 113
plasminogen activator inhibitor 1 (PAI-1) 100, 114, 254
plasminogen activator inhibitor 1 (SERPINE1) 100, 114, 254
plasminogen activator inhibitors (PAIs) 119
plasminogen activators 100–101, 107–111, 113, 116, 118–119, 122–123, 132, 139, 141
PLAT, *see* tissue-type plasminogen activator
platelet-activating factors 31, 100
platelet aggregation 100, 105–106, 123, 139, 570, 572, 586
platelet-derived growth factor 267, 572
PML-RARA fusion protein 622–623
POLDIP2, *see* polymerase delta-interacting protein 2

polmacoxib 84–86
poly ADP ribose polymerase inhibitors (PARP) 15
polyamine oxidase 399
polycystic kidney disease (PKD) 583
polyketide synthase cluster 732
polyketides 538, 729, 731
polymerase delta-interacting protein 2 (POLDIP2) 256
polymorphisms 33–34, 272, 403, 519, 521, 568, 580, 582, 587
Polyoxyl 35 castor oil (EL35) 383–384
polyoxyl 40 hydrogenated castor oil (RH40) 383–384, 389
polypharmacology 674
polyunsaturated fatty acid (PUFA) 568
Pompe disease 178, 642
positron emission tomography (PET) 191, 403
potential ligand as MTDLs 676
potential target proteins 676
PP, *see* parental plasmid
PPARG, *see* peroxisome proliferator-activated receptor gamma
prasugrel 106, 356, 358
pravastatin 546–547, 554
precursor-directed biosynthesis 727, 734, 736
pregnenolone 538
PRIMA-1 626
pro-apoptotic proteins 280, 626
pro-drugs 523
  AOX1-dependent activation 523
prodigiosin 732–733, 737–738
prodrug 104, 335, 356, 539, 644, 651–653, 658, 660, 662
prodrugs 355–356, 358, 536, 643–644
progesterone 536–537, 540, 547–548, 551–552, 555–556
proinsulin 46, 56, 62
  recombinant 46, 56–57
Proleukin 172, 181
Prolyse® 112
pronase E 45, 54
propargylamine 400, 417–418, 420, 442–443, 449–453, 455, 463
propargylamine inactivators 418
propargylated compounds 449
propranolol 83, 356, 543
proprotein convertase subtilisin kexin 9 inhibitors (PCSK9) 15
prostacyclin 100, 568–570
prostacyclin (PGI2) 100, 568–570
prostacyclin (PGI2) synthase 570
prostaglandin (PH2) 79, 105–106, 255, 264, 282
prostaglandin E1 714
prostaglandin G/H synthase 1 (PTGS1) 255
prostaglandin synthase 105
prostaglandins 85, 273, 535
prostanoids 568, 570–571
prostate cancer 2, 4, 15, 28, 320, 326, 610, 643, 658
prostate carcinomas 316
PROTACs 598, 601–610
proteases 53–55, 107, 119–120, 122–125, 127, 129, 132, 176, 180, 191–192, 210–212, 214, 229, 232, 234, 353, 640, 651
proteasomal degradation 599, 601, 606
protein clearance 53
protein engineering 160–161, 163, 165, 167, 169, 171, 173, 175, 184, 192, 546–547, 559, 644, 701
protein fusions 46, 55
protein hormones 181

protein kinase A (PKA) 236
protein kinase C (PKC) 254, 265, 580
protein kinase C isoforms 254
protein libraries 162
protein opsonization 661
protein phosphatase 2A 581
protein refolding 42
protein therapeutics 160–162, 175, 177, 179, 181, 183–185, 193
  market 160, 193
proteinase K 45, 54
protein–glycan coupling technology 689, 696
proteome homeostasis 315
proto-oncogenes 618, 620
prourokinase 112
prunifoleine 461–462
pseudogenization 511, 523–524, 526
Pseudomonas putida 317, 335, 538, 732
Pseudomonas putida KT2440 733, 738
psoriasis 2, 4, 12, 15, 187–188
psoriatic arthritis 2, 12, 15, 187
PTGS1, *see* prostaglandin G/H synthase 1
PUFA, *see* polyunsaturated fatty acid
pulmonary disease 249, 253
pulmonary fibrosis 249
pulmonary hypertension 9, 262, 268
Pulmozyme 51, 172, 178
pyrrolidine dithiocarbamate (PDTC) 293

Q-SiteFinder 676
QSAR, *see* quantitative structure-activity relationship
QSAR-perturbation approach 680
quantitative structure-activity relationship (QSAR) 389, 679
quercetin 281, 491, 625
quinine oxidase 523

R-6-hydroxybuspirone 543
R3C 46
RAC1, *see* ras-related C3 botulinum toxin substrate 1
random mutagenesis 164–165, 542, 544, 546–547, 550–551, 553, 555, 557–558
random mutation 729
randomized clinical trials 21
rapamycin 731–732, 734, 737
ras-related C3 botulinum toxin substrate 1 (RAC1) 256
RAS-targeted therapeutics 608
rational drug design (RDD) 674
RDD, *see* rational drug design
rDNA technology 213–214
reactive nitrogen species (RNS) 249, 252
reactive oxygen species (ROS) 235, 249–250, 254, 271, 333, 437, 481, 486, 525, 575, 653
  mitochondrial ROS (mtROS) 255
  ROS-mediated pathways 250
real-world data 22
real-world evidence (RWE) 23
receptor-interacting serine-threonine kinase 2 (RIPK2) 601
receptor tyrosine kinases 602
recombinant DNA technology 15, 56, 109, 141, 160, 324
recombinant proteins 44, 46, 50, 55, 59, 180, 646
  glycosylation 46, 59
redox homeostasis 249, 274–275, 277

renovascular disease (RVD) 580
renovascular hypertension 578, 581
respiratory chain 277, 409
respiratory problems 249
resveratrol 31, 283, 461, 723–724
reteplase 107, 114
retinitis pigmentosa 75
Reversan 625
reversed-phase HPLC (RP-HPLC) 220–221
RH40, *see* polyoxyl 40 hydrogenated castor oil
rhARGI, *see* arginase
rhein 281, 288
rheumatic heart disease 2
rhinovirus 3C proteases 55
Rho kinase 580
Rhodobacter capsulatus B10S 732–733
riboflavin 400, 722
RIPK2, *see* receptor-interacting serine-threonine kinase 2
rituximab 14
rivastigmine 420, 438–439, 450, 474, 476–478
RNA binding motif protein 39 606
RNA interference 605
RNase 45, 52–53, 63, 690
RNS, *see* reactive nitrogen species
ROS, *see* reactive oxygen species
ROS signaling 275
Rotarix 47
RP-HPLC 220
RUNX1 transcription factor 629
RVD, *see* renovascular disease
RWE, *see* real world evidence

Saccharomyces cerevisiae 56, 404, 639, 729–730
Saccharopolyspora erythraea 538
safinamide 410, 413–414
Sanfilippo syndrome 641
SAR, *see* structure-activity relationship
sarcomas 617
saruplase 112–113
SCARB1, *see* scavenger receptor class B member 1
scavenger receptor class B member 1 254–255
scavenger receptor class B member 1 (SCARB1) 254–255
Scheie syndrome 178
SCLC, *see* small cell lung cancer
SDM, *see* site directed mutagenesis
SEER's database 617
selectins (P-, E-, L-) 258, 292, 705
selegiline 402, 409–410, 414, 417, 452–453, 463, 486
semicarbazide-sensitive amine oxidase (SSAO) 398
semisynthesis 727–730, 736
sequence saturation mutagenesis (SeSAM) 165
serine protease inhibitors (SERPINS) 122
serine proteases 107, 111, 117, 120–122, 124–125, 127–134, 136–137, 139, 192, 211–212
serotonin 85, 397, 403, 407–408, 410, 413, 420, 434–435, 475, 485–486, 521
serpin 122, 229
SERPINE1, *see* plasminogen activator inhibitor 1
SERPINS, *see* serine protease inhibitors
serrapeptase 140
Serratia marcescens 732–733, 737
SeSAM, *see* sequence saturation mutagenesis

SGLT-2, *see* sodium–glucose cotransporter 2 inhibitors
SHC1, *see* signalling adapter SHC-transforming protein 1
she, *see* soluble epoxide hydrolase
sialic acids 699, 704, 708
Siglec receptors 704, 708
signal transduction 33, 235, 249, 253, 275, 278
signalling adapter SHC-transforming protein 1 (SHC1) 254
sildenafil 28, 81, 293
simvastatin 234, 382–383, 727
single guide RNA 649
single nucleotide polymorphisms (SNPs) 403
single-step conversions 738
site-directed glycosylation 696
site saturation mutagenesis (SSM) 165
skin burns 233–234
skin cancers 233
skin disease treatment 235, 240
skin explants 524
skin infections 232–233
SLC-0111 87
SLC2A4/GLUT4, *see* solute carrier family 2, facilitated glucose transporter member 4
SLS, *see* sodium lauryl sulfate
small cell lung cancer (SCLC) 24, 320, 540
small ubiquitin-related modifier (SUMO) 213
SN38, *see* 7-ethyl-10-hydroxy-camptothecin
SNIPER(ER) 600
SNIPERs 597–600, 602–610
SNPs, *see* single nucleotide polymorphisms
SOD, *see* superoxide dismutase
sodium lauryl sulfate (SLS) 383–384, 389
sodium-potassium-chloride (NKCC2) transporter 581
sodium–glucose cotransporter 2 inhibitors (SGLT-2) 15
soft tissue sarcoma 5, 320
solid phase peptide synthesis (SPPS) 698
solid tumors 88, 174, 187, 618–619, 621–622, 632
solinase 115
soluble epoxide hydrolase (sEH) 569–570
  inhibitors
    AR9281 585
    GSK2256294 585–586
solute carrier family 2, facilitated glucose transporter member 4 (SLC2A4/GLUT4) 254
somatic cells 618, 628
sorafenib 86, 603
spinal muscular atrophy 5, 7
splenomegaly 621, 639
SPPS, *see* solid phase peptide synthesis
SSAO, *see* semicarbazide-sensitive amine oxidase
SSM, *see* site saturation mutagenesis
St. John's Wort 542
staggered extension process (StEP) 166
staphylokinase 107, 113, 118, 132
statins 716
stealth strategies 657, 661
StEP, *see* staggered extension process
steroids 187, 535, 537, 540, 557–558, 567
sterol demethylase 538
Streptag II 55
streptococcal pharyngitis 734
Streptococcus pneumoniae 52
streptokinase 106–110, 112–113, 118, 122, 132, 141, 644

Streptomyces avermitilis 731
Streptomyces coelicolor CH999 538
Streptomyces hygroscopicus 731–732
streptozotocin (STZ) 267–268, 271
structure-activity relationship (SAR) 389, 435, 440, 679
structure-based drug design 404, 675
STZ, *see* streptozotocin
subtilisin 15, 20, 62, 132, 137, 139
subtilisin family 139
sulfaphenazole 577
sulfonamides 76–81, 83, 365–366, 454
  diuretic drugs 79
  drug interactions 76–77, 79
sulthiame 81–83
SUMO, *see* small ubiquitin-related modifier
superoxide dismutase (SOD) 274–276, 655
SuperProDesigner 63
SURFNET 676
synthetic peptides 207, 209, 215, 234
Szeto-Schiller (SS) family peptides 291

t-AUCB 574
T-cell receptors 688
T-cell signaling 700
T-cells 276, 630–631, 699, 703
t-PA, *see* tissue plasminogen activator
T4 lysozyme 653
TAC, *see* total antioxidant capacity
tacrine 31, 438, 440, 446, 452–453, 455, 457–458, 460–461, 463, 474, 476–477
  toxicity 453, 477
tadalafil 293
TAFI, *see* thrombin-activatable fibrinolysis inhibitor
tamoxifen 651–653
Tanimoto similarity coefficient 676
Taq DNA polymerase 164, 189–190
tarenflurbil 494
tau protein 481
taxol 538–539, 557, 724, 727–728
Taxus baccata 728
Taxus brevifolia 724, 727
Taxus chinensis 538
TCA cycle 255
tenecteplase 107, 114, 116
terpenoids 491, 549
TERT gene 628
terutroban 584
testosterone 537, 540, 544, 548, 553
tetracycline 714
TEV 46
thalidomide 11, 602
thalidomides 602, 606
therapeutic antibodies 607
therapeutic enzymes 1, 11, 13, 15, 30–31, 106, 141, 638, 645, 651, 658
therapy with living drugs 623
Thioredoxin 79, 213
thioridazine 507, 513, 516–517, 526
Thomsen–Friedenreich (TF) antigen 696, 699
threonine proteases 211
thrombin 46, 55, 100–101, 103–105, 122
thrombin-activatable fibrinolysis inhibitor (TAFI) 100
thrombin inhibitors 104–105
thrombolytic drugs 107, 109, 111, 113, 115, 117, 119, 121, 123,

125, 127, 129, 131, 133, 135, 137, 139
plasmin-like 119
thrombolytic enzymes 102, 108, 119, 124–125, 129, 133, 141
algal sources 125
bacterial 133
earthworm 119
fungal 129
microbial 119, 141
non-microbial 119
plant-based 124
snake venom 119
thrombosis 644
thromboxane-A synthase 106
thromboxane A2 105, 568, 570–571
thromboxane A2 (TxA2) 105, 568, 570–571
thromboxane A2 synthase 570
thromboxane modulators 583
thymic stromal lymphopoeitin 8
thymidine phosphorylase 641
ticagrelor 106
ticlopidine 106
tirofiban 106
tissue plasminogen activator (t-PA) 100, 107, 112, 644
tissue-type plasminogen activator (PLAT) 107, 254
TKI 621, 624
TME, *see* tumor microenvironment
Tn antigen 699–700
Tn glycan 699–700
TNF-α, *see* tumor necrosis factor-α
tobacco etch virus protease 55
α-tocopherol 277, 291
tolfenamic acid 544
topiramate 81, 83, 89–90
topoisomerase inhibitors 624
topothecan 624
total antioxidant capacity (TAC) 282
TP53 mutations 627
transgenic plants 536
translation termination factor 602
transposase 733
tranylcypromine 401–402, 409–410, 412, 414–416
TREX-system 731–733
triphenylphosphonium (TPP+) derivatives 291
trypanosomiasis 2
Trypsin 44–46, 212
recombinant 44, 46, 213
tryptamine 434, 486
tuberculosis 2, 415
tumor angiogenesis inhibition 229
tumor cells 176, 191, 603, 606, 617–620, 622–632, 643–644, 652–653, 691, 700, 707
multidrug resistance 624
stem cell like features 627
therapy resistance mechanisms 625, 627
tumor-initiating cells 627
tumor microenvironment (TME) 86
tumor necrosis factor α (TNF-α) 179, 184, 189
tumor suppressor genes 50, 618
tumor suppressors 618
tumor therapy 600
tumorigenesis 586–587, 707
tumors 2, 4, 32, 75, 86, 88, 173–174, 178, 187, 191, 597, 600, 617–622, 627–629, 631–632, 640, 648, 655, 662, 696, 699
immunotherapies 623
patient outcome 622

treatment 2, 88, 178, 619, 621–622, 631–632, 648
Turner Syndrome 182
TxA2, *see* thromboxane A2
tyramine 408–409, 414, 416, 434, 437, 486
tyrosine kinase 24, 186, 580, 602, 621, 702, 704
tyrosine kinase inhibitors 621
tyrosine kinase pathway 702, 704

UA, *see* ursolic acid
ubiquitin-proteasome system (UPS) 598
ubiquitylation 598–599, 601–602
UDP-glucuronosyl transferase 34
UDP-*N*-acetylglucosamine 2-epimerase/*N*-acetylmannosamine-kinase 708
UGT, *see* uridine diphosphateglucuronosyltransferase
ulcerative colitis 11–12
UPS, *see* ubiquitin-proteasome system
uric acid 251, 269–270, 274–275, 277, 287, 638
uridine diphosphateglucuronosyltransferase (UGT) 389
urokinase 107, 110, 112–113, 116, 121–123
urolithins 491
ursolic acid (UA) 369, 371, 389

valdecoxib 84–86
vancomycin 737
Vanilla planifolia 722
vanillin 524
vardenafil 293
Vascular Adhesion Protein-1 398
vascular cell adhesion molecule (VCAM) 571
vascular inflammation 258, 571
VCAM, *see* vascular cell adhesion molecule
VDEPT, *see* virus-directed enzyme prodrug therapy
verapamil 382–383, 543, 625
vesicular reuptake system (VMAT2) 407
VHL, *see* von Hippel-Lindau
VHL-recruiting degrader 608
virtual screening procedures (VSP) 273
virus-directed enzyme prodrug therapy (VDEPT) 644
virus-like particles 52, 651
visomitin 291
vitamin D 554
vitamin D2 538, 540, 547, 554
vitamin K antagonists 103
VMAT2, *see* vesicular reuptake system
von Hippel-Lindau (VHL) 601
von Willebrand factor (vWF) 100
VSP, *see* virtual screening procedures
VTNR polymorphism 403
vWF, *see* von Willebrand factor

WHO, *see* World Health Organization
whole genome sequencing 618, 621
wild-type CYP enzymes 534, 537, 539, 542
World Health Organization (WHO) 27, 50

wound healing 100, 179, 232, 234, 237, 696, 701

X-linked hypophosphataemia 8
xanthine dehydrogenase 270, 514
xanthine oxidase 15, 258, 267, 269, 514, 526
xanthine oxidase inhibitors 15
xanthine oxidases 249
xanthine oxidoreductases 507

Yescarta 5–6

zeaxanthin 732–733
zinc finger protein 602
ziprasidone 523
zonisamide 81, 83–84, 89–90

"*This book is an important addition to the literature in this field. It not only summarizes the importance of enzymes as targets for pharmaceutical drug research in the past but also shows that there is still enormous potential in the future. Motivated by Peter Grunwald, a large group of experts have shared their specialist knowledge. The book a treasure for anyone working or doing research in the field.*"

Prof. Theo Dingermann
Goethe University, Germany

"*This book represents an outstanding scientific work. It covers the state of the art, challenges, and key achievements of research focusing on the use of enzymes for therapeutic purposes. It discusses the fundamentals of enzyme function and its applications and shows how this fantastic research field has been explored in drug discovery and innovation for gaining a better understanding of enzymes and their use for a better quality of life.*"

Prof. Cláudio Viegas Jr.
Universidade Federal de Alfenas, Brazil

This book provides an overview of the world market of therapeutic enzymes and enzyme inhibitors, rare diseases, orphan drugs, the costs of drug development and therapies, and enzymes in downstream processing of pharmaceuticals. It discusses carbonic anhydrase inhibitors and their multiple drug interactions, carboxylesterase inhibitors for pharmaceutical applications, employment of inhibitors for the treatment of neurodegenerative diseases, use of engineered proteins, bioactive peptides, and fibrinolytic enzymes for thrombolytic therapy, and enzymes important for the design and development of new drugs/drug metabolites such as aldehyde oxidases and cytochrome P450 enzymes and the role the latter play in vascular biology and pathophysiology. The treatment of cancer is explored in connection with enzymatic amino acid deprivation therapies and new drugs that act as chemical degraders of oncogenic proteins. The book also introduces the resistance mechanisms of cancer. Furthermore, it provides an insight into the relationship between pathological conditions of cardiovascular disease and oxidative stress. The text also focuses on the potential use of nanoparticles as carriers for enzymes with medical relevance, computer-aided drug design for the identification of multi-target directed ligands, and the development of improved therapeutics through a glycan-"designer" approach. It concludes with an introduction to the chemoenzymatic synthesis of drugs.

Peter Grunwald studied chemistry at the Universities of Saarbrücken and Hamburg, Germany. He graduated in the field of high-frequency spectroscopy and then became a staff member of the Institute of Physical Chemistry. After receiving his PhD in physical chemistry, he founded a biotechnology research group. He was appointed professor in 2001. His research interests focus on immobilized biocatalysts, kinetics of enzymes in organic solvents, and interactions between biocatalysts and heavy metal ions. Prof. Grunwald is also interested in chemical education, including curriculum development. He has authored a textbook on biochemistry and is an editorial board member of *Catalysts*.

V709
ISBN 978-981-4800-61-7
9 789814 800617

Jenny Stanford
Publishing